Development of a Novel Oral Peptide Therapy to Target the IL-23 Receptor in IL-23-Mediated Diseases

Time: 1:30 pm
day: Day One Translational Track PM


  • Combining high potency with gastrointestinal stability provides an approach to overcome typically low systemic bioavailability of peptide therapeutics administered orally
  • Targeting the IL-23 pathway with an oral peptide that binds the IL-23 receptor has the potential to be a first-in-class therapy for psoriasis and other IL-23-mediated diseases